The panel discussed optimal treatment cycles for enfortumab vedotin/pembrolizumab. The panel shared their thoughts on the EV-302 study. The panel kicked off with conversations about data released at ESMO, including EV-302 and CheckMate 901. The panel shares their hopes for the future of bladder cancer treatment. The panel shares tips for community oncologists who may not be familiar with treating patients with EV/pembro. The panel shares treatment sequencing decisions based on a few patient scenarios. The panel discussed the double antibody-drug conjugate trial that assessed sacituzumab govitecan plus EV. The panel shares lessons learned from the phase THOR study. The panel discusses the CheckMate 901 study results. The panel discussed how the EV-302 data compare to the previous JAVELIN paradigm. The panel discusses the "buzz" around the EV-302 study. The panel shares insights on future advancements in the field. The panel discussed the "innovative design" of the phase 2 ENZA-p study presented at ESMO 2023. The panel discusses treatment-related adverse events, including hematologic toxicities, xerostomia, and more. The panel discuss patient interest in receiving radioligand therapy in the context of cost and access challenges. The panel discusses results of the phase 3 PSMAfore study presented at ESMO 2023. The panel talks "pearls of wisdom" with radioligand therapy. The panel discusses recommended frequency of scans for patients receiving radioligand therapy, PSA response, and more. The panel discusses excitement for the future in kidney cancer: CAR-T, adjuvant checkpoint inhibitors, and sequencing. The panel shared thoughts on the TIDE-A study and best practices for starting and stopping TKI therapy in RCC patients